Plain-English translation of NCT04763447 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Asthma research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial tests whether people with severe allergic asthma can safely stop taking omalizumab after their asthma has been well controlled for at least three years. Omalizumab is a biologic medication (a drug made from living cells) that helps reduce severe asthma attacks. The study wants to know if the medication can be stopped without asthma getting worse again, or if people need to keep taking it long-term.
While this medication has been used successfully for many years to control severe allergic asthma, doctors don't have clear guidelines about how long people should take it. Some patients improve so much that their asthma stays under control even after stopping the treatment, but others' asthma gets worse again. This study will help doctors understand which patients can safely stop the medication and which ones need to keep taking it.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either stop taking the medication completely or keep taking it at your usual dose. If you're assigned to stop, you'll quit right away (not gradually taper down). Both groups will be followed over time to see how your asthma responds. Throughout the study, your doctors will monitor your asthma control with periodic check-ups to see if stopping the medication caused any problems.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
France